WallStreetZenWallStreetZen

NASDAQ: CGTX
Cognition Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CGTX

Based on 2 analysts offering 12 month price targets for Cognition Therapeutics Inc

Min Forecast
$3.00+79.64%
Avg Forecast
$3.50+109.58%
Max Forecast
$4.00+139.52%

Should I buy or sell CGTX stock?

Based on 2 analysts offering ratings for Cognition Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CGTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CGTX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their CGTX stock forecasts and price targets.

CGTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-08
lockedlocked$00.00+00.00%2025-06-26

1 of 1

Forecast return on equity

Is CGTX forecast to generate an efficient return?

Company
-271.77%
Industry
127.2%
Market
-48.11%
CGTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CGTX forecast to generate an efficient return on assets?

Company
-97.35%
Industry
47.5%
CGTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CGTX earnings per share forecast

What is CGTX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.42
Avg 2 year Forecast
-$0.28
Avg 3 year Forecast
-$0.26

CGTX revenue forecast

What is CGTX's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$22.5M
Avg 2 year Forecast
$18.0M
Avg 3 year Forecast
$11.0M

CGTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CGTX$1.67$3.50+109.58%Strong Buy
PLX$1.53N/AN/A
IMRX$3.35$13.25+295.52%Strong Buy
CHRS$1.07$4.03+276.17%Buy
IKT$1.70N/AN/A
View Top Biotech Stocks

Cognition Therapeutics Stock Forecast FAQ

Is Cognition Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CGTX) stock is to Strong Buy CGTX stock.

Out of 2 analysts, 1 (50%) are recommending CGTX as a Strong Buy, 1 (50%) are recommending CGTX as a Buy, 0 (0%) are recommending CGTX as a Hold, 0 (0%) are recommending CGTX as a Sell, and 0 (0%) are recommending CGTX as a Strong Sell.

If you're new to stock investing, here's how to buy Cognition Therapeutics stock.

What is CGTX's earnings growth forecast for 2025-2027?

(NASDAQ: CGTX) Cognition Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.42%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.25%.

Cognition Therapeutics's earnings in 2025 is -$32,993,000.On average, 4 Wall Street analysts forecast CGTX's earnings for 2025 to be -$30,674,643, with the lowest CGTX earnings forecast at -$37,470,821, and the highest CGTX earnings forecast at -$24,245,826. On average, 3 Wall Street analysts forecast CGTX's earnings for 2026 to be -$20,814,674, with the lowest CGTX earnings forecast at -$27,184,714, and the highest CGTX earnings forecast at -$11,020,830.

In 2027, CGTX is forecast to generate -$19,102,772 in earnings, with the lowest earnings forecast at -$19,102,772 and the highest earnings forecast at -$19,102,772.

What is CGTX's revenue growth forecast for 2025-2027?

(NASDAQ: CGTX) Cognition Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.78%.

Cognition Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast CGTX's revenue for 2025 to be $1,653,124,478, with the lowest CGTX revenue forecast at $1,653,124,478, and the highest CGTX revenue forecast at $1,653,124,478. On average, 1 Wall Street analysts forecast CGTX's revenue for 2026 to be $1,322,499,582, with the lowest CGTX revenue forecast at $1,322,499,582, and the highest CGTX revenue forecast at $1,322,499,582.

In 2027, CGTX is forecast to generate $808,194,189 in revenue, with the lowest revenue forecast at $808,194,189 and the highest revenue forecast at $808,194,189.

What is CGTX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CGTX) forecast ROA is -97.35%, which is lower than the forecast US Biotechnology industry average of 47.5%.

What is CGTX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CGTX price target, the average CGTX price target is $3.50, with the highest CGTX stock price forecast at $4.00 and the lowest CGTX stock price forecast at $3.00.

On average, Wall Street analysts predict that Cognition Therapeutics's share price could reach $3.50 by Aug 8, 2026. The average Cognition Therapeutics stock price prediction forecasts a potential upside of 109.58% from the current CGTX share price of $1.67.

What is CGTX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CGTX) Cognition Therapeutics's current Earnings Per Share (EPS) is -$0.67. On average, analysts forecast that CGTX's EPS will be -$0.42 for 2025, with the lowest EPS forecast at -$0.51, and the highest EPS forecast at -$0.33. On average, analysts forecast that CGTX's EPS will be -$0.28 for 2026, with the lowest EPS forecast at -$0.37, and the highest EPS forecast at -$0.15. In 2027, CGTX's EPS is forecast to hit -$0.26 (min: -$0.26, max: -$0.26).

What is CGTX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CGTX) forecast ROE is -271.77%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.